# A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

Source: https://onco.cc/trials/nct05938270/  
OnCo record `nct05938270` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is completed.

## Summary

The registry lists NCT05938270 as completed, last updated 2026-06-30. Enrolment is 113 actual participants. Interventions: Saruparib (AZD5305), Darolutamide, No Treatment. Primary measures include Fold change in % γH2AX positive cells from baseline value in tumour samples. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-10-06
- Registry id: NCT05938270
- Phase: 1
- Setting: An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer (ASCERTAIN)
- Sponsor: AstraZeneca
- Enrolled: 113

## Sources

- ClinicalTrials.gov NCT05938270: https://clinicaltrials.gov/study/NCT05938270

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)

---
JSON: https://onco.cc/api/v1/entities/nct05938270.json